Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

John Eikelboom 1, * Jacqueline Bosch 1 Stuart Connolly 1 Jessica Tyrwitt 1 Keith Fox 2 Eva Muehlhofer 3 Christoph Neumann 3 Christoph Tasto 3 Shrikant Bangdiwala 1 Rafael Diaz 4 Marco Alings 5 Gilles Dagenais 6 Darryl Leong 1 Eva Lonn 1 Alvaro Avezum 7 Leopoldo Piegas 8 Petr Widimsky 9 Alexander Parkhomenko Deepak Bhatt 10 Kelley Branch 11 Jeffrey Probstfield 12 Patricio Lopez-Jaramillo 13 Lars Rydén 14 Nana Pogosova 15 Katalin Keltai 16 Matyas Keltai 16 Georg Ertl 17 Stefan Stoerk 17 Antonio Dans 18 Fernando Lanas 19 Yan Liang 20 Jun Zhu 20 Christian Torp-Pedersen 21 Aldo Maggioni 22 Patrick Commerford 23 Tomasz Guzik 24 Thomas Vanassche 25 Peter Verhamme 25 Martin O'Donnell 26 Andrew Tonkin 27 John Varigos 27 Dragos Vinereanu 28 Camillo Felix 29 Jae-Hyung Kim 30 Khairul Ibrahim Basil Lewis Kaj Metsarinne 31 Victor Aboyans 32, 33 Phillippe Gabriel Steg 34 Masatsugu Hori 35 Ajay Kakkar 36 Sonia Anand 1 Andre Lamy 1 Mukul Sharma 1 Salim Yusuf 1 
* Auteur correspondant
Abstract : Abstract Aims To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long term open label extension (LTOLE). Methods and results Of 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1–1 191 days). During LTOLE, the incident events per 100 patient years were: for the primary outcome (cardiovascular [CV] death, stroke, or myocardial infarction [MI]) 2.35 (95% CI 2.11–2.61), mortality 1.87 (1.65–2.10), stroke 0.62 (0.50–0.76) and MI 1.02 (0.86–1.19), with confidence intervals that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major bleeding were 1.01 (0.86–1.19) and for minor bleeding 2.49 (2.24–2.75), compared with 1.67 (1.48–1.87) and 5.11 (95% CI 4.77–5.47), respectively, during the randomized treatment phase with the combination. Conclusion In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-unilim.archives-ouvertes.fr/hal-03676188
Contributeur : Elisabeth Grelier Connectez-vous pour contacter le contributeur
Soumis le : lundi 23 mai 2022 - 16:32:13
Dernière modification le : mardi 24 mai 2022 - 03:48:56

Identifiants

Collections

Citation

John Eikelboom, Jacqueline Bosch, Stuart Connolly, Jessica Tyrwitt, Keith Fox, et al.. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, Oxford Academy, 2022, ⟨10.1093/ehjcvp/pvac023⟩. ⟨hal-03676188⟩

Partager

Métriques

Consultations de la notice

11